The Current and Future State of Immune Checkpoint Inhibitors in NSCLC

Expert oncologists reflect on recent clinical trial data to elucidate the evolving treatment landscape of checkpoint inhibition in non–small cell lung cancer.

EP. 1: Paradigm for Immunotherapy in Advanced Non-Small Cell Lung Cancer

July 15th 2022

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

EP. 2: Advanced NSCLC: The Advent of Frontline IO Monotherapy

July 15th 2022

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

EP. 3: Toxicity Profiles of Immunotherapy Agents in Advanced NSCLC

July 22nd 2022

A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.

EP. 4: Advanced NSCLC: IO Monotherapy Selection Based on PD-L1 Expression

July 22nd 2022

Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.

EP. 5: Chemoimmunotherapy Combinations in Advanced NSCLC

July 29th 2022

Shifting their focus to chemoimmunotherapy combinations in advanced NSCLC, experts review clinical trial data from KEYNOTE-189, IMpower150, and EMPOWER-Lung 3.

EP. 6: Discontinuing Chemoimmunotherapy in Advanced NSCLC

July 29th 2022

A brief discussion on when it is appropriate to discontinue chemoimmunotherapy in patients with advanced non–small cell lung cancer.

EP. 7: Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227

August 5th 2022

Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.

EP. 8: CheckMate 9LA: Dual IO Therapy With Chemotherapy in Advanced NSCLC

August 5th 2022

Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.

EP. 9: Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLC

August 12th 2022

Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.